Drug Search Results
More Filters [+]

ABT-639

Alternative Names: abt-639
Latest Update: 2024-03-15
Latest Update Note: PubMed Publication

Product Description

ABT-639 is a peripherally acting highly selective T-type Ca(v)3.2 calcium channel blocker that has demonstrated analgesic efficacy in preclinical models and may have the potential to reduce spontaneous fiber activity. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26035253/)

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ABT-639

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases|Neuralgia|Neuropathic Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-005127-40

P2

Completed

Neuropathic Pain

2012-11-13

M13-383

P2

Completed

Peripheral Nervous System Diseases|Neuropathic Pain|Neuralgia

2012-11-01

2010-024359-99

P2

Completed

Neuropathic Pain

2011-10-26

M11-891

P2

Completed

Neuralgia|Neuropathic Pain

2011-10-01

Recent News Events